{
    "clinical_study": {
        "@rank": "94348", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die. Acitretin may be an effective treatment for skin disease and\n      skin cancer.\n\n      PURPOSE: Phase II trial to study the effectiveness of acitretin in treating patients who\n      have skin disease or skin cancer."
        }, 
        "brief_title": "Acitretin in Treating Patients With Skin Disease or Skin Cancer", 
        "condition": "Non-Melanomatous Skin Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Skin Neoplasms", 
                "Carcinoma, Basal Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES: I. Determine the long-term safety and efficacy of acitretin in patients with\n      psoriasis, cutaneous disorders of keratinization, multiple basal cell carcinomas, or other\n      retinoid-responsive diseases or malignancies.\n\n      OUTLINE: Patients receive oral acitretin daily in the absence of disease progression or\n      unacceptable toxicity.\n\n      PROJECTED ACCRUAL: A total of 130 patients will be accrued for this study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS: Diagnosis of psoriasis, cutaneous disorders of keratinization, or\n        other retinoid-responsive disorders or malignancies OR Diagnosis of multiple basal cell\n        carcinomas resulting from one of the following: Nevoid basal cell carcinoma syndrome\n        Xeroderma pigmentosum Arsenical insecticide exposure Sunlight exposure X-irradiation\n        Widespread involvement (e.g., psoriasis involving 10% or more of body surface area OR\n        Severe, recalcitrant localized involvement (e.g., keratoderma palmaris et plantaris)\n        Female patients must have disease that is severe and recalcitrant to all other standard\n        therapies\n\n        PATIENT CHARACTERISTICS: Age: Any age Performance status: Not specified Life expectancy:\n        Not specified Hematopoietic: Not specified Hepatic: No persistently abnormal liver\n        function tests SGOT or SGPT no greater than 3 times upper limit of normal (ULN) Renal: No\n        persistently abnormal renal function tests Creatinine no greater than 3 times ULN Other:\n        No persistent pretreatment hypertriglyceridemia (greater than 300 mg/dL) No significant\n        neurological, musculoskeletal, or other internal medical disorder that would preclude\n        retinoid therapy Not pregnant Negative pregnancy test Fertile patients must use effective\n        contraception during and for 3 years after study\n\n        PRIOR CONCURRENT THERAPY: No chronic intake of excessive vitamin A exceeding 25,000 IU/day"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "firstreceived_date": "July 11, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00020956", 
            "org_study_id": "CDR0000068733", 
            "secondary_id": "NCI-77-AR-0172"
        }, 
        "intervention": {
            "intervention_name": "acitretin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Acitretin"
        }, 
        "keyword": "basal cell carcinoma of the skin", 
        "lastchanged_date": "July 23, 2008", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/NCI-77-AR-0172"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Bethesda", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "20892"
                }, 
                "name": "Intramural Research Program"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "The Evaluation of Oral Acitretin in the Treatment of Psoriasis, Cutaneous Disorders of Keratinization, Multiple Basal Cell Carcinomas and Other Retinoid-Responsive Diseases", 
        "overall_official": {
            "affiliation": "National Cancer Institute (NCI)", 
            "last_name": "John J. DiGiovanna, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00020956"
        }, 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "December 2001", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2001"
    }, 
    "geocoordinates": {
        "Intramural Research Program": "38.985 -77.095"
    }
}